Novo Nordisk AS (OCSE:NOVO B)
kr 757.3 9.7 (1.3%) Market Cap: 3.36 Til Enterprise Value: 3.35 Til PE Ratio: 35.72 PB Ratio: 27.97 GF Score: 97/100

Q3 2020 Novo Nordisk A/S Earnings Call Transcript

Oct 30, 2020 / 12:00PM GMT
Release Date Price: kr205.28 (-3.41%)
Operator

Hello, and welcome to the Q3 2020 Novo Nordisk A/S Earnings Conference Call. (Operator Instructions)

Today, I'm pleased to present Mr. Lars Fruergaard Jørgensen. Please go ahead with your meeting.

Lars Fruergaard JÃ;rgensen;S;President
Novo Nordisk A;CEO & Member of Management Board

¸ - /- -

Thank you very much. Welcome to this Novo Nordisk conference call regarding our performance for the first 9 months of 2020 and our financial outlook for 2020. I'm Lars Fruergaard Jørgensen, the CEO of Novo Nordisk. With me, I have our Chief Financial Officer, Karsten Munk Knudsen; and our Chief Science Officer, Mads Krogsgaard Thomsen. Also present and available for the Q&A session are Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest; and our Investor Relations officers. Today's earnings release and the slides for this call are available on our website, novonordisk.com. Please note that this conference call is being webcasted live, and a recording will be

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot